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Transesophageal echocardiography (TEE) has been increas-
ingly used for the evaluation of patients with a suspected
cardiac source of embolization (1). Transesophageal echo-
cardiography findings such as spontaneous echocardio-
graphic contrast, atrial septal aneurysm (ASA), patent
foramen ovale (PFO), aortic atheroma, left atrial thrombi,
and cardiac masses have been related to an increased risk of
embolization (2–8) based on a higher prevalence in patients
with suspected embolism compared with those who under-
went TEE for other reasons. These findings have also been
useful to risk-stratify patients with atrial fibrillation (9,10).
In the last 15 years, significant efforts have been made to
understand the clinical significance of these findings and to
identify the optimal treatment (11–16).
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The management of patients with PFO is controversial.
Early transthoracic studies suggested that the prevalence of
PFO was high in the general population (25% to 33% of all
individuals) but significantly higher in younger patients with
cryptogenic stroke (17–19). Recent case-control studies
have shown that in patients55 years old, the prevalence of
PFO is three times greater in patients with suspected
ischemic events and that the presence of ASA is six times
greater than in the general population (15). Mechanistic
hypotheses have been postulated, including paradoxical
embolization of thrombi from the peripheral venous system,
direct embolization from thrombi formed within the inter-
atrial septum, particularly in those with ASA, and concur-
rent association of right atrial (RA) abnormalities, such as
the Eustachian valve and Chiari network (20–22).
There is a significant association of ASA and PFO both
in large cohort populations and in patients with suspected
cardiac source of embolization (23,24). Atrial septal aneu-
rysm is associated with right-to-left interatrial shunting. In
addition, patients with PFO who have an associated ASA
are thought to be at higher risk of embolization (25).
The Patent Foramen Ovale in Cryptogenic Stroke Study
(PICSS) included 630 patients with stroke adjudged non-
cardioembolic who underwent TEE voluntarily or for clin-
ical reasons. All patients were part of the Warfarin Aspirin
Recurrent Stroke Study (WARSS) (26). From this popula-
tion, Homma et al. (21), in this issue of the Journal,
attempted to identify the mechanism for the increased
stroke risk in patients with ASA and PFO. They also
assessed the efficacy of medical therapy for preventing stroke
recurrence or death in patients with ASA, PFO, and a RA
anatomy predisposing to paradoxical embolization. The
current study is an extension of previous data published by
the same group (16). They found that a large PFO and
prominent Eustachian valve or RA filamentous strands were
more frequent in patients with ASA than those without
ASA (21). After two years of follow-up with treatment of
warfarin or aspirin, patients with ASA and PFO had no
significant difference in time to recurrent stroke or death
compared with those with neither finding (15.9% vs. 14.5%,
hazard rate 1.08). Likewise, predisposing RA anatomy
posed no risk in excess of the risk borne by those without it.
Among patients with PFO and ASA, there was no signif-
icant difference in time to recurrent stroke or death between
warfarin and aspirin (16% vs. 15.6%; hazard rate 1.0).
Previous data supporting an ominous effect of RA anatomy
in patients with interatrial abnormalities are soft at best
(27,28), and that was confirmed in the study.
These results are in marked contrast with several other
studies that have demonstrated that PFO, size of PFO, and
the presence of ASA confer higher risk of stroke, primarily
in younger patients. In a recent multicenter prospective
European study that included 581 patients with ischemic
stroke, the recurrent stroke rate for patients with ASA and
PFO was 15.2%, versus 4.2% among patients with neither
abnormality (25).
Thus, the current results should be interpreted with
caution. The patient population in PICSS is not represen-
tative of the PFO population in general or of the PFO
population with ischemic stroke. The parent study,
WARSS, excluded ischemic stroke patients with an inferred
cardioembolic source (26). The PFO population in PICSS
would not contain patients with a PFO identified before
WARSS entry for whom the PFO was considered to be
causally related to the qualifying ischemic stroke. These
patients could be considered “asymptomatic” with regard to
the PFO. The patients who had a PFO identified by TEE
after WARSS entry were apparently not highly suspect for
harboring a causal or “symptomatic” PFO, because the TEE
was not performed during the evaluation for the WARSS-
qualifying stroke. In contrast, the retrospective studies
showing high risk for PFO and ASA included selected
patients at higher risk for cardioembolic source because they
were deemed to require TEE as part of their evaluation for
stroke. The differences in the PICSS results and prospective
studies showing high risk for PFO and ASA in patients
with cryptogenic stroke are unexplained, but patient popu-
lation differences are likely important, as well as the criteria
to classify a stroke as cryptogenic. In the largest prospective
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study of stroke patients ages 18 to 55, none of the patients
with PFO was excluded from the cryptogenic group. The
combination of ASA and PFO was a marker or recurrent
stroke—but not the presence of PFO or ASA alone (25).
What are the implications for management from these
results? As Dr. Halperin and Fuster (20) pointed out in a
similar editorial discussing this group’s previous article, the
lack of superiority of warfarin over aspirin in the PICSS is
indirect evidence that thromboembolism related to atrial
arrhythmias or venous disease may not be the predominant
mechanism of stroke in patients with PFO. First, the
diagnosis of PFO-mediated paradoxical embolism remains
presumptive, and cryptogenic embolism is not necessarily
synonymous with paradoxical embolism. Second, both PFO
and cryptogenic stroke may coexist without causal relation,
and such patients would have a low recurrent stroke rate.
Third, other mechanisms, such as a genetic predisposition
or “paradoxical” crossing of vasoactive substances that would
otherwise be deactivated in the pulmonary circulation,
cannot be eliminated. The increasingly recognized associa-
tion of migraine and PFO and its resolution after PFO
closure supports this hypothesis (20,29).
The study results imply that medical therapy alone may
be protective against recurrent stroke and death in patients
with non-embolic stroke. They also suggest that the benefits
of a mechanical (surgical or percutaneous) approach to
treatment of PFO may be difficult to demonstrate because
of a low recurrent event rate with anti-thrombotic or
anti-platelet therapy alone. Although the mechanical ap-
proach has been safe and effective in uncontrolled studies
(30,31), adverse events can occur after surgical correction,
such as atrial fibrillation, post-percardiotomy syndrome, and
even stroke (32,33). Percutaneous closure has shown en-
couraging results, and the newest devices offer promise for
low procedural morbidity and long-term durability (30,34)
but must be compared with the best medical therapy before
this form of management can be recommended as standard
of care. Comparisons to medical treatment studies are
hampered by the patient selection. Most medical treatment
studies include patients with only one previous ischemic
embolic episode. On the contrary, percutaneous PFO clo-
sure appears to be particularly successful in the subgroup
with multiple prior embolic events (30,31).
These interventional studies speak to the dilemma of
management of patients with stroke in whom a PFO or
ASA is identified. Patients in the interventional studies
were thought to be “symptomatic” from the PFO. The
stroke patients in PICCS with PFO were “asymptomatic”
or, at the least, judged to be non-cardioembolic. With
carotid artery disease, the presence of stenosis or the
anatomic or hemodynamic characteristics of the carotid
stenosis are much less important than whether or not the
artery is judged to be symptomatic. Symptomatic status is
the major determinant of recurrent stroke on medical
therapy, and of the risks or the long-term benefits of
non-medical therapies (carotid endarterectomy or stent)
(35,36). For patients with PFO, determining symptomatic
status in the setting of stroke continues to be a diagnostic
challenge. Up to 40% of stroke patients may be classified as
cryptogenic, but some of these are likely cardioembolic.
Likewise, for some patients with an ischemic stroke, a PFO
thought to be “cardioembolic” might be innocent or at least
non-causally related to the stroke. This overlap may result in
inappropriate patient management, particularly if the stroke
adjudication is utilized to guide therapy.
For PFO and ASA, what are the criteria to be used in
assessing whether the lesion is causally related to the stroke?
What makes a PFO symptomatic? Demonstration of hy-
percoagulable states and detection of stasis-related thrombi
in the peripheral venous system are important (20,37). In
those patients, warfarin is likely to be more useful than
anti-platelet agents. Recurrent ischemic stroke without
other identifiable cause could be another criterion, and for
these patients either warfarin or, particularly for patients
with recurrent events receiving medical therapy or those
with contraindications to anticoagulation, percutaneous clo-
sure should be considered. The PFO size, the presence of
ASA, and the other anatomic characteristics addressed in
PICSS cannot yet be discarded as irrelevant criteria as to
whether or not a particular PFO confers increased risk for
patients receiving medical therapy. Interventional studies,
planned and underway, will include PFO patients who
would be excluded from studies of cryptogenic stroke and so
will provide data still unavailable regarding the importance
of atrial anatomy.
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